Clinical trials: sponsored by Novo Nordisk A/S
Osteopenia, Osteoporosis, Age-related Bone Loss
Senolytics to Improve Osteoporosis Therapy
This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and…
- Trial name
- SENIOR (NCT06018467)
- Testing
- Dasatinib 100 Mg Oral Tablet, Quercetin 1.250 mg (oral), Nicotinamide Riboside 1g (oral)
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Odense University Hospital
Growth Hormone Deficiency in Children
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).
- Trial name
- REAL4 (NCT03811535)
- Testing
- Somapacitan, Norditropin®
- Where
- 139 sites in United States, Algeria and 24 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Cardiovascular Diseases, Endocrinology
BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe
Lack of adherence to treatment is a widespread issue worldwide, which leads to higher healthcare utilisation rates and even premature death.
- Conditions
- Cardiovascular Diseases, Endocrinology, Inmunology, Neurology
- Trial name
- BEAMER (NCT06856902)
- Testing
- B-COMPASS implementation
- Where
- 10 sites in Germany, Italy and 6 more
- Volunteers
- 6,190 people
- Sponsor
- Technical University of Madrid
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the…
- Trial name
- CLEOPATTRA (NCT07207811)
- Testing
- NNC6019-0001
- Where
- 299 sites in United States, Argentina and 18 more
- Volunteers
- 1,280 people
- Sponsor
- Novo Nordisk A/S
Obesity, Childhood
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head.
- Trial name
- GLOW (NCT06977438)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 1,020 people
- Sponsor
- University of Minnesota
Overweight and Obesity, Type 2 Diabetes
Hedonic and Homeostatic Appetite Control in Obesity and Type 2 Diabetes in the Context of Meal and Exercise Timing
The overall aim is to investigate effects of acute exercise on ad libitum energy intake and study whether this differs between morning and evening in individuals with overweight/obesity with or without type 2 diabetes (T2D).
- Trial name
- TIMEX (NCT05768958)
- Testing
- Exercise, Control
- Where
- Denmark
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Type 2 Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema.
- Trial name
- NCT06221969
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 197 sites in United States, Argentina and 6 more
- Volunteers
- 1,024 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema.
- Trial name
- REIMAGINE 5 (NCT06534411)
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 163 sites in United States, Argentina and 12 more
- Volunteers
- 1,023 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight.
- Trial name
- REIMAGINEYOUNG (NCT07282613)
- Testing
- CagriSema (Cagrilintide B and Semaglutide I)
- Where
- 58 sites in United States, Argentina and 8 more
- Volunteers
- 80 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or…
- Trial name
- NCT07607587
- Testing
- Cagrilintide
- Where
- 13 sites in United States
- Volunteers
- 114 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Semaglutide Health Outcomes and Patient Adherence in Australia
This observational study aims to generate real-world evidence on the use of semaglutide in adults with overweight or obesity receiving care through a digital weight loss service (DWLS) programme in Australia.
- Trial name
- SHAPED-AU (NCT07881770)
- Testing
- Semaglutide
- Where
- Australia
- Volunteers
- 10,000 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07855133
- Testing
- Semaglutide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07868354
- Testing
- Tirzepatide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Liver Transplant; Complications, Diabetes Mellitus
Semaglutide vs Sitagliptin
The effect of once daily dosing of oral Semaglutide versus once daily dosing Sitagliptin on glycemic control, body weight, and safety and tolerability will be compared in Liver Transplant Recipients with poorly-controlled…
- Conditions
- Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT05195944
- Testing
- Semaglutide Treatment, Sitagliptin 100mg
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- University Health Network, Toronto
Cardiometabolic Diseases
Sustainable Diets and Cardiometabolic Health
This study aims to investigate the effects of sustainable diets on traditional and novel cardiometabolic risk factors. The primary objective is: To test the effects of a sustainable diet on traditional cardiometabolic risk…
- Trial name
- PlanetDiet (NCT07189676)
- Testing
- Dietary advice (PHD), Dietary advice (Ovo-lacto-vegetarian diet), Dietary advice (control)
- Where
- Denmark
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Non-alcoholic Steatohepatitis
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.
- Trial name
- ESSENCE (NCT04822181)
- Testing
- Semaglutide
- Where
- 558 sites in United States, Argentina and 37 more
- Volunteers
- 1,205 people
- Sponsor
- Novo Nordisk A/S
Fatty Liver Disease
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat.
- Trial name
- NCT07214870
- Testing
- NNC4005-001
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR…
- Trial name
- NCT06260709
- Testing
- NNC6019-0001
- Where
- 38 sites in United States, Canada and 8 more
- Volunteers
- 88 people
- Sponsor
- Novo Nordisk A/S
Haemophilia B
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
The purpose of this study is to collect data on adverse events from third party registries that include information about adverse events from patients with haemophilia B treated with nonacog beta pegol.
- Trial name
- NCT03690336
- Testing
- Nonacog beta pegol
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency in Children, Born Small for Gestational Age
Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
Participants are free to decide if they want to take part in this study or not. The study will be conducted to collect information about the influence of adherence to growth hormone therapy with Norditropin® in children and…
- Trial name
- NCT03972345
- Testing
- Norditropin® FlexPro®
- Where
- Germany
- Volunteers
- 750 people
- Sponsor
- Novo Nordisk A/S